En la búsqueda de respuestas sobre el origen y la evolución de nuestro vasto universo, los científicos se han adentrado en los misterios de una singularidad, un punto en el espacio-tiempo donde las leyes de la física convencional se desmoronan y las dimensiones conocidas …
NANOBIOTIX announced updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology.
InxMed Co., Ltd announces that clinical data of Ifebemtinib, a highly potent and selective oral inhibitor of focal adhesion kinase, in platinum-resistant recurrent ovarian cancer and triple-negative breast cancer has been presented at the 2023 European Society for Medical Oncology Congress taking place October 20-24 in Madrid, Spain.
BerGenBio ASA announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer were presented during the European Society of Clinical Oncologists Annual Meeting 2023.
Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company announced that it has granted AstraZeneca Plc a global online STARMAP® license.
Nanoform grant Global STARMAP® AI License to AstraZeneca Read More »
Celltrion USA announced that the U.S. Food and Drug Administration has approved ZYMFENTRA® for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn’s disease following treatment with an infliximab product administered intravenously.
Infinity Laboratories is thrilled to officially unveil its new brand identity at the AAPS 2023 PharmaSci 360 Annual Meeting from October 22nd to the 25th in Orlando, Florida.
Infinity Laboratories Unveils New Brand at AAPS 2023 PharmaSci 360 in Orlando, FL Read More »
Exelixis, Inc. announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors and a second cohort of patients with advanced extra-pancreatic NET.
Amgen announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® in combination with Vectibix®.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.
